Literature DB >> 1826011

Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.

C Hivroz1, E Fischer, M D Kazatchkine, C Grillot-Courvalin.   

Abstract

The regulatory role of CR1 and CR2 on B cell activation and proliferation has been investigated by using B cells from patients with chronic lymphocytic leukemia. The chronic lymphocytic leukemia B cells are clonal expansions of B lymphocytes frozen at specific stages of activation. They displayed two patterns of response upon surface Ig (sIg) cross-linking in terms of in vitro proliferation and intracellular free Ca2+ mobilization: cells from patient F (first pattern) proliferated in the presence of mitogenic anti-mu antibodies, whereas cells from patient A (second pattern) did not respond to sIg cross-linking but proliferated in the presence of low m.w. B cell growth factor and IL-2. Coculture of A or F cells with C3b-bearing SRBC led to a two- to four-fold increase in thymidine incorporation in cultures containing low m.w. B cell growth factor but not in cultures containing rIL-2. This enhanced proliferation was inhibited by F(ab')2 polyclonal rabbit antihuman CR1 antibodies. Only cells which proliferated in the presence of anti-mu (cells F) responded to cross-linking of sIg with a rise in intracellular Ca2+. No increase in calcium mobilization was observed after co-cross-linking of CR1 and sIg on A and F cells with mAb or polyclonal anti-CR1 antibodies. Co-cross-linking of CR2 with sIg only led to an enhanced intracellular Ca2+ rise in F cells but not in A cells. The lack of CR2-mediated synergy in Ca2+ rise in A cells indicates that the synergy occurs only if there is a proper coupling of sIg to phospholipase C. CR1-induced proliferation of B cells does not involve the signaling pathways of sIg. These results provide additional evidences for the role of C3 fragments in modulation of human B cell activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826011

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

Authors:  H Molina; V M Holers; B Li; Y Fung; S Mariathasan; J Goellner; J Strauss-Schoenberger; R W Karr; D D Chaplin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

2.  Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells.

Authors:  J A Halperin; A Taratuska; A Nicholson-Weller
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

3.  Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

Authors:  Isabel Y Pappworth; Christine Hayes; Jason Dimmick; B Paul Morgan; V Michael Holers; Kevin J Marchbank
Journal:  Immunobiology       Date:  2011-06-25       Impact factor: 3.144

4.  Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney.

Authors:  Anuja Java; M Kathryn Liszewski; Dennis E Hourcade; Fan Zhang; John P Atkinson
Journal:  Mol Immunol       Date:  2015-08-07       Impact factor: 4.407

5.  Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes.

Authors:  A K Matsumoto; D R Martin; R H Carter; L B Klickstein; J M Ahearn; D T Fearon
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

6.  Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.

Authors:  M Lotz; E Ranheim; T J Kipps
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

Review 7.  Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.

Authors:  Jack Mellors; Tom Tipton; Stephanie Longet; Miles Carroll
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

8.  Crohn's Disease Patients in Remission Display an Enhanced Intestinal IgM⁺ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System.

Authors:  Sophie Preisker; Ann-Kathrin Brethack; Arne Bokemeyer; Dominik Bettenworth; Christian Sina; Stefanie Derer
Journal:  Cells       Date:  2019-01-21       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.